Body contouring device maker sees accelerating demand from practices treating post-weight-loss patients on semaglutide.
Apyx Medical reported that demand for its Renuvion helium plasma and AYON body contouring systems is accelerating, driven by the surge in GLP-1 agonist use. Patients on semaglutide and tirzepatide who achieve rapid weight loss are increasingly seeking skin tightening and body sculpting—a shift that plays directly to Renuvion's strengths in minimally invasive body contouring.
The trend validates a thesis that emerged in 2024: GLP-1 disruption, while initially damaging to facial injectables, is creating new revenue streams in body procedures. Renuvion's radiofrequency-assisted liposuction and skin-tightening mechanism is particularly suited to post-weight-loss patients seeking non-surgical alternatives to traditional body lift surgery.
Apyx sees GLP-1 boom fueling demand for Renuvion and AYON body contouring systems.
For practice owners considering device investment, Apyx's guidance suggests that body contouring will be a growth category through 2026. The capital requirement is higher than injectables, but patient volume and procedure pricing in this segment remain strong.
Source: original report ↗
Frequently asked questions
Is Renuvion in high demand right now?
Yes. Apyx Medical reported accelerating demand for Renuvion helium plasma and AYON body contouring systems, driven by the surge in GLP-1 agonist use. Practices are seeing increased patient volume from semaglutide and tirzepatide users seeking skin tightening after rapid weight loss.
Why are GLP-1 patients choosing body contouring procedures?
Patients achieving rapid weight loss on semaglutide and tirzepatide are seeking skin tightening and body sculpting to address loose skin and contour irregularities. Renuvion's radiofrequency-assisted liposuction and skin-tightening mechanism is particularly suited to these post-weight-loss patients as a non-surgical alternative to traditional body lift surgery.
How long will body contouring demand stay strong?
Apyx's guidance indicates that body contouring will remain a growth category through 2026. The GLP-1 trend is expected to continue driving patient volume in this segment.
Should I invest in a body contouring device for my medspa?
Body contouring is projected to be a strong growth category through 2026 with solid patient volume and procedure pricing. The capital requirement is higher than injectables, but the revenue potential and market demand make it worth evaluating for practices positioned to serve post-weight-loss patients.
What's the difference between Renuvion and traditional body lift surgery?
Renuvion is a minimally invasive radiofrequency-assisted system that combines liposuction with skin tightening, while traditional body lift surgery is invasive and requires longer recovery. Renuvion appeals to post-weight-loss patients seeking non-surgical alternatives with faster downtime.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
